Assembling synergistic peptide-drug conjugates for dual-targeted treatment of cancer metastasis

We here report assembling synergistic peptide-drug conjugates (asPDCs) with the therapeutic activity arising from both peptide and chemodrug moieties for treatment of cancer metastasis. The asPDCs were created via co-assembling one protein-derived therapeutic peptide with its conjugate functionalized with paclitaxel (PTX), due to the strong assembling propensity of the peptide. While the asPDC showed the remarkable cytotoxicity against breast tumor cells due to the combinatorial effect, treatment of tumor cells with the asPDCs significantly inhibited cell migration and invasion through depolymerization of micro -filaments and stabilization of microtubules by the peptide and PTX, respectively. In vivo results suggest the tumor-targeting property of the asPDCs and confirm their synergistic therapeutic roles in inhibition tumor growth and prevention of cancer metastasis. Our findings demonstrate the combining therapeutic effect and targeting property of the assembling synergistic peptide-drug conjugates, thus providing an alternative strategy for design of peptide-drug conjugates for disease treatment in the future.(c) 2022 Elsevier Ltd. All rights reserved.

Automated summary

This study reports the assembly of synergistic peptide-drug conjugates for the treatment of cancer metastasis. The conjugates were created by co-assembling a protein-derived therapeutic peptide with paclitaxel, resulting in remarkable therapeutic effects and tumor-targeting properties.